Provided by Tiger Trade Technology Pte. Ltd.

Werewolf Therapeutics, Inc.

0.9274
-0.0159-1.69%
Volume:949.62K
Turnover:874.67K
Market Cap:45.02M
PE:-1.24
High:0.9400
Open:0.9350
Low:0.9000
Close:0.9433
52wk High:2.38
52wk Low:0.2700
Shares:48.54M
Float Shares:47.91M
Volume Ratio:0.23
T/O Rate:1.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7503
EPS(LYR):-1.3300
ROE:-119.86%
ROA:-27.39%
PB:2.76
PE(LYR):-0.70

Loading ...

Werewolf Therapeutics Completes Key Early Trial For WTX-124 In Hard-To-Treat Cancers

TIPRANKS
·
Aug 28

Press Release: $hareholder Alert: the M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

Dow Jones
·
Aug 24

U.S. Stocks on the MOVE-NetEase, Werewolf Therapeutics, JP Morgan

Reuters
·
Aug 21

Sector Update: Healthcare Stocks Edge Higher Pre-Bell Friday

MT Newswires Live
·
Aug 21

Why Is Penny Stock Werewolf Therapeutics (HOWL) Up Today?

TIPRANKS
·
Aug 21

U.S. Stocks on the MOVE-Ubiquiti, BJ's Wholesale, Arbutus

Reuters
·
Aug 21

Werewolf Therapeutics Shares Leap on Reverse Merger, Asset Sale

Dow Jones
·
Aug 21

Werewolf More than Doubles on Ambros Therapeutics Merger

Reuters
·
Aug 21

Werewolf Therapeutics Announces USD 150 Million Oversubscribed Private Placement of Shares, Pre-Funded Warrants

Reuters
·
Aug 21

Werewolf Therapeutics Agrees to Merge with Ambros Therapeutics in All-Stock Deal

Reuters
·
Aug 21

Werewolf Therapeutics - Combined Company to Operate as Ambros Therapeutics, to Trade as Ambx on NASDAQ

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics: Stockholders of Ambros Will Receive Newly Issued Shares of Co's Stock Stock Pursuant to a Formula Set Forth in Deal Agreement

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics - Deal Expected to Close by Q1 2027 Subject to Approvals

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics - Stockholders to Own 6.8%, Ambros Stockholders 71.7%, Private Placement Investors 21.5% of Combined Co

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics: Ambros Expects Combined Co to be Fully Funded Through Topline Results from Pivotal Crps-Rise Phase 3 Clinical Trial

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics: Exchange is Based on Implied Value of Ambros of $500 Mln (Before Private Placement) and Implied Value of Co of $47.5 Mln

THOMSON REUTERS
·
Aug 21

Werewolf Therapeutics - Combined Company to be Led by Ambros Therapeutics Leadership Team with Joseph (Jay) Hagan as CEO

THOMSON REUTERS
·
Aug 21

Press Release: Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

Dow Jones
·
Aug 21

NASDAQ Trade Halt Halt News Pending at 07:55 Am

Reuters
·
Aug 21

Top Premarket Gainers

MT Newswires Live
·
Aug 21